Drug repurposing for cardiovascular diseases: New targets and indications for probenecid
British Journal of Pharmacology · 2023-03 · 180 (6) · 685-700
DOI: 10.1111/bph.16001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, online erschienen am 26.12.2022. Verfasst von Zsófia Onódi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Heart Failure, Myocardial Ischemia, Coronary Artery Disease. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Human Capacities, Horizon 2020 Framework Programme, Hungarian Academy of Sciences.
Abstract (Originalsprache)
The available pharmacological options in the management of cardiovascular diseases such as ischaemic heart disease and subsequent heart failure are effective in slowing the progression of this condition. However, the long‐term prognosis is still poor, raising the demand for new therapeutic strategies. Drug repurposing is a time‐ and cost‐effective drug development strategy that offers approved and abandoned drugs a new chance for new indications. Recently, drugs used for the management of gout‐related inflammation such as canakinumab or colchicine have been considered for drug repurposing in cardiovascular indications. The old uricosuric drug, probenecid, has been identified as a novel therapeutic option in the management of specific cardiac diseases as well. Probenecid can modulate myocardial contractility and vascular tone and exerts anti‐inflammatory properties. The mechanisms behind these beneficial effects might be related inhibition of inflammasomes, and to modulation purinergic–pannexin‐1 signalling and TRPV2 channels, which are recently identified molecular targets of probenecid. In this review, we provide an overview on repurposing probenecid for ischaemic heart disease and subsequent heart failure by summarizing the related experimental and clinical data and propose its potential repurposing to treat cardiovascular diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
- HCEMM-SU Cardiometabolic Immunology Research Group, Semmelweis University, Budapest, Hungary.
- MTA-SE Momentum Cardio-Oncology and Cardioimmunology Research Group, Semmelweis University, Budapest, Hungary.
- Department of Internal Medicine, Division of Cardiovascular Health and Disease, College of Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio, USA.
- Pharmahungary Group, Szeged, Hungary.
ORCID-Profile: Zsófia Onódi, Péter Ferdinandy, Zoltán V Varga
Förderung
- Ministry of Human Capacities
- Horizon 2020 Framework Programme
- Hungarian Academy of Sciences
- National Research, Development and Innovation Office
- Emberi Eroforrások Minisztériuma
- Magyar Tudományos Akadémia
- Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
Zitieren
APA
Onódi, Z., Koch, S., Rubinstein, J., Ferdinandy, P., & Varga, Z. V. (2023). Drug repurposing for cardiovascular diseases: New targets and indications for probenecid. British Journal of Pharmacology, 180(6), 685-700. https://doi.org/10.1111/bph.16001
Vancouver
Onódi Z, Koch S, Rubinstein J, Ferdinandy P, Varga ZV. Drug repurposing for cardiovascular diseases: New targets and indications for probenecid. British Journal of Pharmacology. 2023;180(6):685-700. doi:10.1111/bph.16001
BibTeX
@article{Ondi2023,
author = {Onódi, Zsófia and Koch, Sheryl and Rubinstein, Jack and Ferdinandy, Péter and Varga, Zoltán V},
title = {Drug repurposing for cardiovascular diseases: New targets and indications for probenecid},
journal = {British Journal of Pharmacology},
year = {2023},
volume = {180},
number = {6},
pages = {685--700},
doi = {10.1111/bph.16001}
}
EUVIMED